1586 related articles for article (PubMed ID: 18600190)
21. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
[TBL] [Abstract][Full Text] [Related]
23. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
26. A combination vaccine against measles, mumps, rubella and varicella.
Knuf M; Faber J; Barth I; Habermehl P
Drugs Today (Barc); 2008 Apr; 44(4):279-92. PubMed ID: 18536786
[TBL] [Abstract][Full Text] [Related]
27. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months.
Zepp F; Behre U; Kindler K; Laakmann KH; Pankow-Culot H; Mannhardt-Laakmann W; Beckers F; Descamps D; Willems P
Eur J Pediatr; 2007 Aug; 166(8):857-64. PubMed ID: 17541639
[TBL] [Abstract][Full Text] [Related]
29. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.
Ma SJ; Li X; Xiong YQ; Yao AL; Chen Q
Medicine (Baltimore); 2015 Nov; 94(44):e1721. PubMed ID: 26554769
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
Gatchalian S; Leboulleux D; Desauziers E; Bermal N; Borja-Tabora C
Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):589-97. PubMed ID: 15115135
[TBL] [Abstract][Full Text] [Related]
31. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
[TBL] [Abstract][Full Text] [Related]
32. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age.
Rinderknecht S; Michaels MG; Blatter M; Gaglani M; Andrews W; Abughali N; Chandreshekaran V; Trofa AF
Pediatr Infect Dis J; 2011 Oct; 30(10):e179-85. PubMed ID: 21617573
[TBL] [Abstract][Full Text] [Related]
34. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
Llenas-García J; Rubio R; Hernando A; Arrazola P; Pulido F
AIDS Care; 2013 Aug; 25(8):980-9. PubMed ID: 23244745
[TBL] [Abstract][Full Text] [Related]
35. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
[TBL] [Abstract][Full Text] [Related]
37. Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.
Rüger G; Gabutti G; Rümke H; Rombo L; Bernaola E; Diez-Domingo J; Martinon-Torres F; Høgh B; Konstantopoulos A; Fiquet A; Thomas S; Eymin C; Baudin M
Pediatr Infect Dis J; 2012 Nov; 31(11):1166-72. PubMed ID: 22772170
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
Santos EMD; Noronha TG; Alves IS; Cruz RLS; Ferroco CLV; Brum RC; Oliveira PMN; Siqueira MM; Lima MC; Ramos FLP; Bragagnolo CM; Camacho LAB; Maia MLS
Mem Inst Oswaldo Cruz; 2019 Mar; 114():e180517. PubMed ID: 30843921
[TBL] [Abstract][Full Text] [Related]
39. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
Casabona G; Berton O; Singh T; Knuf M; Bonanni P
Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: a phase II, randomized, double-blind trial.
Huang LM; Lee BW; Chan PC; Povey M; Henry O
Hum Vaccin Immunother; 2013 Jun; 9(6):1308-15. PubMed ID: 23425607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
